StockNews.com assumed coverage on shares of Assembly Biosciences (NASDAQ:ASMB – Get Rating) in a research report sent to investors on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, Mizuho lowered their target price on Assembly Biosciences from $14.00 to $3.00 and set a buy rating for the company in a report on Wednesday, November 16th.
Assembly Biosciences Stock Performance
Shares of ASMB stock opened at $1.23 on Thursday. The stock has a 50 day simple moving average of $1.49 and a two-hundred day simple moving average of $1.52. Assembly Biosciences has a fifty-two week low of $0.82 and a fifty-two week high of $2.42.
Institutional Investors Weigh In On Assembly Biosciences
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate.
- Get a free copy of the StockNews.com research report on Assembly Biosciences (ASMB)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.